Bicycle Therapeutics PLC (BCYC)

NASDAQ: BCYC · IEX Real-Time Price · USD
46.73 -1.72 (-3.54%)
Jan 18, 2022 1:37 PM EST - Market open
Market Cap1.37B
Revenue (ttm)11.77M
Net Income (ttm)-66.22M
Shares Out29.40M
EPS (ttm)-2.87
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume239,402
Open47.20
Previous Close48.44
Day's Range45.92 - 49.34
52-Week Range20.67 - 62.08
Beta-0.26
AnalystsBuy
Price Target73.64 (+57.6%)
Earnings DateNov 4, 2021

About BCYC

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune c...

IndustryBiotechnology
IPO DateMay 23, 2019
CEOKevin Lee
Employees109
Stock ExchangeNASDAQ
Ticker SymbolBCYC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for BCYC stock is "Buy." The 12-month stock price forecast is 73.64, which is an increase of 57.60% from the latest price.

Price Target
$73.64
(57.60% upside)
Analyst Consensus: Buy

News

Bicycle Therapeutics Announces Continued Clinical Progress and Updates to Management Team

CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycli...

1 week ago - Business Wire

7 A-Rated Biotechs to Buy for the Long Run

The one thing the pandemic has shown us is biotechs are changing the way we treat diseases. These A-rated biotechs are great examples.

1 month ago - InvestorPlace

Bicycle Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

2 months ago - Business Wire

Bicycle Therapeutics to Present Four Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cel...

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

2 months ago - Business Wire

Bicycle Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycli...

2 months ago - Business Wire

Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle® Tumor-targeted Immune Cell Agonist...

CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycli...

2 months ago - Business Wire

Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT7480 Program in the Journa...

CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycli...

2 months ago - Business Wire

Bicycle Therapeutics Announces Expansion of Genentech Immuno-Oncology Collaboration

CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycli...

2 months ago - Business Wire

Bicycle Therapeutics Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwri...

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

3 months ago - Business Wire

Bicycle Therapeutics Announces Pricing of Upsized Public Offering of $175 Million of American Depositary Shares

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

3 months ago - Business Wire

Bicycle Therapeutics Announces Proposed $125,000,000 Public Offering of American Depositary Shares

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

3 months ago - Business Wire

Bicycle Therapeutics Stock Falls After Interim Data Of Toxin Conjugates In Ovarian Cancer Trial

Bicycle Therapeutics plc (NASDAQ: BCYC) has reported interim Phase I trial results for BT5528 and preliminary findings from the ongoing dose-escalation portion of the BT8009 trial. Two BT5528 monotherap...

3 months ago - Benzinga

Bicycle Therapeutics Announces Interim BT5528 Phase I Clinical Trial Results and Preliminary Results from Ongoing BT8...

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

3 months ago - Business Wire

Bicycle Therapeutics PLC Sponsored ADR (BCYC) Surges 7%: Is This an Indication of Further Gains?

Bicycle Therapeutics PLC Sponsored ADR (BCYC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving...

3 months ago - Zacks Investment Research

Bicycle Therapeutics to Present BT5528 Interim Phase I Data at AACR-NCI-EORTC Virtual International Conference on Mol...

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

3 months ago - Business Wire

3 Biotech Stocks That Soared to New Heights Last Week

Find out what these industry favorites are doing to impress investors.

Other symbols:ADGICERE
4 months ago - The Motley Fool

Bicycle Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycli...

5 months ago - Business Wire

Bicycle Therapeutics PLC Sponsored ADR (BCYC) Is a Great Choice for "Trend" Investors, Here's Why

Bicycle Therapeutics PLC Sponsored ADR (BCYC) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stoc...

5 months ago - Zacks Investment Research

Ionis (IONS) Inks Deal With Bicycle Therapeutics for LICA Drugs

Ionis (IONS) signs a deal with Bicycle Therapeutics to incorporate the latter's optimized Bicycle peptides into its LICA delivery platform.

Other symbols:IONS
6 months ago - Zacks Investment Research

Bicycle, Ionis To Develop Targeted Oligonucleotide Therapeutics

Bicycle Therapeutics plc (NASDAQ: BCYC) announced that Ionis Pharmaceuticals Inc (NASDAQ: IONS) has exercised its option and entered into an exclusive worldwide license and collaboration agreement to de...

Other symbols:IONS
6 months ago - Benzinga

Bicycle Therapeutics Enters Exclusive License and Collaboration Agreement with Ionis to Develop Targeted Oligonucleot...

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

6 months ago - Business Wire

Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at further advancing LICA technology

CARLSBAD, Calif., July 13, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that it has entered into an exclusive licensing agreement with Bicycle Therapeutics plc (NASDAQ...

Other symbols:IONS
6 months ago - PRNewsWire

Here's What Could Help Bicycle Therapeutics PLC Sponsored ADR (BCYC) Maintain Its Recent Price Strength

Bicycle Therapeutics PLC Sponsored ADR (BCYC) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several sto...

6 months ago - Zacks Investment Research

Bicycle Therapeutics Announces Restrictions on Shareholder Attendance at Annual General Meeting to be Held on June 28...

CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycli...

7 months ago - Business Wire

Bicycle Therapeutics to Participate in Upcoming Virtual Investor Conferences

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

7 months ago - Business Wire